Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77,892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Suppression of cytokine release syndrome during CAR-T-cell therapy via a subcutaneously injected interleukin-6-adsorbing hydrogel.
Li X, Gong N, Tian F, Zhang S, Zhang Y, Wang Y, Qing G, Wang Y, Li F, Xu Y, Zhang L, Wang J, Ni Q, Gan Y, Gu C, Jiang H, Huang X, Shi X, Zhang T, Wu Y, Liang XJ. Li X, et al. Among authors: zhang l, zhang s, zhang t, zhang y. Nat Biomed Eng. 2023 Sep;7(9):1129-1141. doi: 10.1038/s41551-023-01084-4. Epub 2023 Sep 11. Nat Biomed Eng. 2023. PMID: 37696984
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies.
Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, Gu C, Zhang S, Chen L, Cheng J, Wang G, Zhou X, Zheng M, Mao X, Jiang L, Wang D, Wang Q, Lou Y, Cai H, Yan D, Zhang Y, Zhang T, Zhou J, Huang L. Wang N, et al. Among authors: zhang s, zhang t, zhang y. Blood. 2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017. Blood. 2020. PMID: 31697824 Free article. Clinical Trial.
A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.
Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, Zhou J. Li C, et al. Among authors: zhang s, zhang w, zhang t. Clin Transl Med. 2021 Mar;11(3):e346. doi: 10.1002/ctm2.346. Clin Transl Med. 2021. PMID: 33784005 Free PMC article. Clinical Trial.
CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
Cao Y, Xiao Y, Wang N, Wang G, Huang L, Hong Z, Meng L, Zhou X, Wang J, Yang Y, Xu H, Zhang S, Xiao M, Chen L, Zheng M, Li C, Mao X, Gu C, Zhang T, Zhang Y, Zhou J. Cao Y, et al. Among authors: zhang s, zhang t, zhang y. Transplant Cell Ther. 2021 Nov;27(11):910.e1-910.e11. doi: 10.1016/j.jtct.2021.08.012. Epub 2021 Aug 20. Transplant Cell Ther. 2021. PMID: 34425260 Free article.
CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity.
Shi J, Zhang Z, Cen H, Wu H, Zhang S, Liu J, Leng Y, Ren A, Liu X, Zhang Z, Tong X, Liang J, Li Z, Zhou F, Huang L, Qin Y, Yang K, Zhang T, Zhu H. Shi J, et al. Among authors: zhang s, zhang t, zhang z. J Hematol Oncol. 2021 Oct 9;14(1):162. doi: 10.1186/s13045-021-01178-z. J Hematol Oncol. 2021. PMID: 34627328 Free PMC article.
77,892 results
You have reached the last available page of results. Please see the User Guide for more information.